Subanesthetic Ketamine Suppresses Locus Coeruleus-Mediated Alertness Effects: A 7T fMRI Study
- PMID: 38833581
- PMCID: PMC11187989
- DOI: 10.1093/ijnp/pyae022
Subanesthetic Ketamine Suppresses Locus Coeruleus-Mediated Alertness Effects: A 7T fMRI Study
Abstract
Background: The NMDA antagonist S-ketamine is gaining increasing use as a rapid-acting antidepressant, although its exact mechanisms of action are still unknown. In this study, we investigated ketamine in respect to its properties toward central noradrenergic mechanisms and how they influence alertness behavior.
Methods: We investigated the influence of S-ketamine on the locus coeruleus (LC) brain network in a placebo-controlled, cross-over, 7T functional, pharmacological MRI study in 35 healthy male participants (25.1 ± 4.2 years) in conjunction with the attention network task to measure LC-related alertness behavioral changes.
Results: We could show that acute disruption of the LC alertness network to the thalamus by ketamine is related to a behavioral alertness reduction.
Conclusion: The results shed new light on the neural correlates of ketamine beyond the glutamatergic system and underpin a new concept of how it may unfold its antidepressant effects.
Keywords: Ketamine; LC functional connectivity; alertness; locus coeruleus; ultra-high field MRI.
© The Author(s) 2024. Published by Oxford University Press on behalf of CINP.
Figures




Similar articles
-
Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.Int J Neuropsychopharmacol. 2025 Jun 6;28(6):pyaf037. doi: 10.1093/ijnp/pyaf037. Int J Neuropsychopharmacol. 2025. PMID: 40411824 Free PMC article. Clinical Trial.
-
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.Cochrane Database Syst Rev. 2015 Sep 29;(9):CD011611. doi: 10.1002/14651858.CD011611.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2021 Oct 8;10:CD011611. doi: 10.1002/14651858.CD011611.pub3. PMID: 26415966 Updated.
-
Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.J Psychopharmacol. 2025 Jun;39(6):577-592. doi: 10.1177/02698811251319456. Epub 2025 Feb 26. J Psychopharmacol. 2025. PMID: 40012166 Free PMC article. Clinical Trial.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. Cochrane Database Syst Rev. 2021. PMID: 34510411 Free PMC article.
References
-
- Abram SV, Roach BJ, Fryer SL, Calhoun VD, Preda A, van Erp TG, Bustillo JR, Lim KO, Loewy RL, Stuart BK, Krystal JH, Ford JM, Mathalon DH (2022) Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. Mol Psychiatry 27:2448–2456. - PMC - PubMed
-
- American Psychiatric Association (2005) Diagnostic and statistical manual of mental disorders (rev.). Arlington; APA.
-
- Aston-Jones G (2005) Brain structures and receptors involved in alertness. Sleep Med 6:S3–S7. - PubMed
-
- Aston-Jones G, Cohen J (2005a) Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol 493:99–110. - PubMed
-
- Aston-Jones G, Cohen JD (2005b) An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28:403–450. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical